Feuerstein's Biotech-Stock Mailbag

Let's get right to it. This week's first email comes from Frank Z., who writes:

"What about SuperGen (SUPG Quote)? The pipeline looks promising, stock perking up, positive outcome with their [Dacogen] EORTC study and [Tuesday's] analyst day sounded promising. You wrote about the stock a year ago how about a little Adam F. biotech rundown?"

The overhang on SuperGen today is the pending results from a European study of its drug Dacogen designed to assess survival in patients with myelodysplastic syndrome (MDS), a cancer-like disease of the bone marrow.

Both Dacogen and Celgene's (CELG Quote) competing drug, Vidaza, are already approved in the U.S. as a treatment for MDS patients. Vidaza, however, has a study included in its Food and Drug Administration label showing it can significantly boost survival; Dacogen does not. ...